Nephrology

Following is a digest of pharmacogenomics journal articles pertaining to nephrology. The SNP•its editorial team selects articles for inclusion based on clinical relevance and scientific validity. Journal articles that are most readily applicable and relevant to practicing clinicians are selected for a SNP•its Study Summary, which discusses findings and clinical implications of a pharmacogenomics study in the context of the larger evidence base.


Article Citation & LinkTypeMonthSNP•its Study Summary
Shuker N et al. A randomized controlled trial comparing the efficacy of CYP3A5 genotype-based with bodyweight-based tacrolimus dosing after living donor kidney transplantation. Am J Transplant. 2015 Dec 29 [Epub ahead of print].Randomized Controlled Trial2015-12
Li JL et al. Interactive effects of CYP3A4, CYP3A5, MDR1 and NR1I2 polymorphisms on tracrolimus trough concentrations in early postrenal transplant recipients. Pharmacogenomics. 2015;16:1355-65.Observational2015-07
Niioka T et al. Effects of CYP3A5 polymorphism and the tacrolimus 12?h concentration on tacrolimus-induced acute renal dysfunction in patients with lupus nephritis. Xenobiotica. 2015 Jul 20 [Epub ahead of print].PK / PD2015-07
Liu LS et al. Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study. Int J Clin Pract Suppl. 2015;(183):43–52.Prospective Cohort2015-05
Cheng Y et al. Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre. Int J Clin Pract Suppl. 2015 May;(183):16–22.Prospective Cohort2015-05
Zununi Vahed S et al. Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipients. Bioimpacts.2015;5:45–54.Review2015-04
Traynor C et al. Association of CYP3A variants with kidney transplant outcomes. Ren Fail. 2015;37:562-6.Prospective Cohort2015-02
Rojas L et al. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. Pharmacogenomics J. 2015;15:38–48.Meta-analysis2015-02
Medeiros M et al. Use of pharmacogenomics in pediatric renal transplant recipients. Front Genet. 2015;6:41.Review2015-02
Niioka T et al. Capability of utilizing CYP3A5 polymorphisms to predict therapeutic dosage of tacrolimus at early stage post-renal transplantation. Int J Mol Sci. 2015;16:1840-54.Prospective Cohort2015-01
Niioka T et al. Capability of utilizing CYP3A5 polymorphisms to predict therapeutic dosage of tacrolimus at early stage post-renal transplantation. Int J Mol Sci. 2014;16:1840–54.Prospective cohort2014-12
Van Gelder T et al. Pharmacogenetics and immunosuppressive drugs in solid organ transplantation. Nat Rev Nephrol. 2014;10:725–31.Systematic Review2014-12
Lancia P et al. Choosing the right dose of tacrolimus. Arch Dis Child. 2014 Nov 21 [Epub ahead of print].Review2014-11
Pazik J et al. Recipient Uridine 5’-Diphospho-glucuronosyltransferase UGT1A9 c.98T>C variant determines transplanted kidney filtration rate. Transplant Proc. 2014;46:2678–82.Retrospective Cohort2014-11
Baek H et al. Early non-steady-state population pharmacokinetics of oral cyclosporine in renal transplant recipients. Drug Des Devel Ther. 2014;8:2241–9.PK2014-11
Hronová K et al. Pharmacogenetics and immunosuppressive drugs. Expert Rev Clin Pharmacol. 2014;7:821–35.Review2014-11
Chand S et al. Genetic polymorphisms and kidney transplant outcomes. Curr Opin Nephrol Hypertens. 2014;23:605–10.Review2014-11
Lalan S et al. Effect of CYP3A5 genotype, steroids, and azoles on tacrolimus in a pediatric renal transplant population. Pediatr Nephrol. 2014;29:2039–49.PK/PD Study2014-10
Chand S et al. Genetic polymorphisms and kidney transplant outcomes. Curr Opin Nephrol Hypertens. 2014;23:605–10.Review2014-10
Bruckmueller H et al. Which genetic determinants should be considered for tacrolimus dose optimization in kidney transplantation? A combined analysis of genes affecting the CYP3A locus. Ther Drug Monit. 2014 Sep 29 [Epub ahead of print].PK/PD Study2014-10
Sharaki O et al. Impact of CYP3A4 and MDR1 gene (G2677T) polymorphisms on dose requirement of the cyclosporine in renal transplant Egyptian recipients. Mol Biol Rep. 2014 Sep [Epub ahead of print].Retrospective cohort2014-09 
Chand S et al. Genetic polymorphisms and kidney transplant outcomes. Curr Opin Nephrol Hypertens. 2014 Sep [Epub ahead of print].Review2014-09 
van Gelder T et al. Pharmacogenetics and immunosuppressive drugs in solid organ transplantation. Nat Rev Nephrol. 2014 Sep [Epub ahead of print].Review2014-09 
Rojas L et al. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies. Pharmacogenomics J. 2014 Sep [Epub ahead of print].Meta-analysis2014-09 
Birdwell K. Role of pharmacogenomics in dialysis and transplantation. Curr Opin Nephrol Hypertens. 2014 Aug; [Epub ahead of print].Review

 
2014-08 
Schena FP. Biomarkers and personalized therapy in chronic kidney diseases. Expert Opin Investig Drugs. 2014;23:1051-4.Editorial2014-08
Chen Z et al. Genetic polymorphisms in IL-2, IL-10, TGF-B1, and IL-2RB and acute rejection in renal transplant patients. Clin Transplant. 2014;28:649-55.Prospective cohort2014-06
Werk AN et al. Identification and characterization of a defective CYP3A4 genotype in a kidney transplant patient with severely diminished tacrolimus clearance. Clin Pharmacol Ther. 2014;95:416-22.Case report2014-04